FDA's Janet Woodcock to retire in early 2024
Janet Woodcock, an FDA legend who for almost 40 years served as acting FDA commissioner, deputy commissioner and CDER director, among other roles, will retire early next year, she confirmed to Endpoints News via email.
Woodcock’s shoes will be difficult to fill as she has served as the face of just about every drug approval decision at the agency since the turn of the century, bringing decades of experience with her. During the pandemic she served in a wider role, as she rotated between the top of the drugs center at the FDA to the head of therapeutics at Operation Warp Speed, leading the drive for work on Covid-targeted mAbs and antivirals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
